Outlook for Pediatric Drug Development Looks Promising, According to the Tufts Center for the Study of Drug Development
15 nov. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 15, 2016) - Resources dedicated to creating medicines to meet the unique needs of children have grown steadily since legislation guiding pediatric drug...
Diabetes Drug Development Is Riskier Compared to All Drug Development, According to the Tufts Center for the Study of Drug Development
20 sept. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 20, 2016) - Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to...
Global Regenerative Medicine Market Is Poised for Strong Growth, According to the Tufts Center for the Study of Drug Development
14 juil. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 14, 2016) - A strong development pipeline for regenerative medicine (RM) therapies aimed at treating a broad range of unmet medical needs signals rapid growth in...
Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers, According to the Tufts Center for the Study of Drug Development
10 mai 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 10, 2016) - Rising drug prices in the United States will lead payers and pharmaceutical benefit managers (PBMs) to increase the number of drugs ineligible for...
Tufts Center for the Study of Drug Development Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published
10 mars 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 10, 2016) - The most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug...
Promise of Immuno-Oncology Therapies Is Boosting R&D Funding and Alliances, According to the Tufts Center for the Study of Drug Development
08 mars 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 8, 2016) - Investments in research and development for new immuno-oncology (I/O) drugs, along with dramatic improvements in complete response rates in trials for new...
New Approaches to Patient Recruitment and Retention Anticipate Structural Change in the Clinical Research Enterprise, Tufts Center for the Study of Drug Development Reports
26 janv. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 26, 2016) - Responding to strong and growing pressures to accelerate the pace at which new medicines are launched, drug developers are innovating clinical study...
Protocol Amendments Improve Elements of Clinical Trial Feasibility, But at High Economic and Cycle Time Cost, According to the Tufts Center for the Study of Drug Development
14 janv. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 14, 2016) - Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of...
Drug Developers Are Working to Boost R&D Productivity, But Need to do More to Achieve Large-Scale Improvements, According to Tufts Center for the Study of Drug Development
07 janv. 2016 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2016) - While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they must also...
Nearly All Later Entrants to Drug Classes Were in Clinical Testing or Regulatory Review Before First-in-Class Approval, According to the Tufts Center for the Study of Drug Development
03 nov. 2015 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 3, 2015) - Nearly all later entrants to drug classes had begun clinical testing or were in regulatory review in the United States before the first drug within a...